NTNicole H. Tobin

Nicole H. Tobin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nicole H. Tobin has a total of 125 co-authors. Here are the top co-authors by number of shared publications:

  • Grace M. Aldrovandi

    Division of Infectious Diseases, Department of Pediatrics, David Geffen School of Medicine at the University of California, Los Angeles, USA

    7 shared publications
  • Fan Li

    Division of Infectious Diseases, Department of Pediatrics, David Geffen School of Medicine at the University of California, Los Angeles, USA

    5 shared publications
  • Grace M. Aldrovandi

    Department of Pediatrics, Division of Pediatric Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles, USA

    3 shared publications
  • Jennifer A. Fulcher

    Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at UCLA

    3 shared publications
  • Otto O. Yang

    Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA

    3 shared publications
  • Adva Gadoth

    Department of Epidemiology, Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles, USA

    2 shared publications

Latest Publications

  • Open Access

    Distinct inflammatory marker profiles of adolescents and young adults among the HIV risk, infection, and treatment spectrum

    by Huan Vinh Dong, Gielenny M. Salem, Tara Kerin, Kwan Hou Tang, Ruth Cortado, Myung Shin-Sim, Elizabeth Mayfield Arnold, Dallas Swendeman, Nicole H. Tobin, Anne W. Rimoin, et al.

    Youth living with or at HIV-risk exhibit distinct immune perturbations during HIV exposure, infection, and antiretroviral therapy (ART). Understanding immune perturbations is critical for development of tailored prevention and enhanced therapeutic strategies. We performed plasma proteomic profiling of 49 biomarkers using Luminex multiplex assay in 262 participants (mean age of 21.9 years), including healthy controls, high-risk youth without HIV (HRY), newly diagnosed youth living with HIV (NY), and previously diagnosed youth on ART for over 24 months (PY), and report distinct immune landscapes. Among HRY, we observe dysregulation of circulating interferon-driven inflammation. NY display overt systemic inflammation at diagnosis, which partially resolves but does not fully normalize within 24 months of ART. PY display largely normalized immune profiles, though circulating signatures consistent with residual checkpoint activation persist. Our results identify conserved and stage-specific, circulating inflammatory modulators and key transcriptional regulators delineating HIV susceptibility, progression, and long-term treatment responses.

  • Open Access

    Altered milk tryptophan and tryptophan metabolites in women living with HIV

    by Nicole H. Tobin, Fan Li, Wentao Zhu, Kathie G. Ferbas, John W. Sleasman, Daniel Raftery, Louise Kuhn, Grace M. Aldrovandi

    Children born to women living with HIV (WLWH) suffer increased morbidity and, in low-income settings, have two to three times the mortality of infants born to women without HIV. The basis for this increase remains elusive. In low-income settings, breastfeeding is recommended because health benefits outweigh the risk of transmission, especially when maternal antiretroviral therapy is provided. We profile the milk metabolome of 326 women with and without HIV sampled longitudinally for 18 months postpartum using global metabolomics. We identify perturbations in several metabolites, including tryptophan, dimethylarginine, and a recently discovered antiviral ribonucleotide, that are robustly associated with maternal HIV infection. Quantitative tryptophan and kynurenine levels in both milk and plasma reveal that these perturbations reflect systemic depletion of tryptophan and alterations in tryptophan catabolism in WLWH. Finally, we validate these signatures of maternal HIV infection in an independent cohort of healthier WLWH. Taken together, our findings demonstrate that milk tryptophan content and availability decrease among WLWH, which may indicate perturbations in milk tryptophan catabolism. The link between this perturbation and the increased morbidity and mortality of children born to WLWH merits further investigation.


  • Open Access

    Altered milk tryptophan and tryptophan metabolites and health of children born to women with HIV

    by Grace Aldrovandi, Nicole Tobin, Fan Li, Wentao Zhu, Kathie Ferbas, John Sleasman, Dan Raftery, Louise Kuhn

    Children born to women with HIV (WWH) suffer increased morbidity and, in low-income settings, have two to three times the mortality of infants born to women without HIV. The basis for this increase remains elusive. In low-income settings, breastfeeding is recommended because health benefits outweigh the risk of transmission, especially when maternal antiretroviral therapy is provided. We profiled the milk metabolome of 326 women sampled longitudinally for 18 months postpartum using global metabolomics. We identify perturbations in several metabolites, including tryptophan, dimethylarginine, and a recently discovered antiviral ribonucleotide, that are robustly associated with maternal HIV infection. Quantitative tryptophan and kynurenine levels in both milk and plasma reveal that these perturbations reflect systemic depletion of tryptophan and alterations in tryptophan catabolism in WWH. Our findings provide intriguing evidence that decreases in tryptophan availability and perturbations in tryptophan catabolism in children born to WWH may contribute to their increased morbidity and mortality.

  • Open Access

    Use of an Ethinyl Estradiol/Etonogestrel Vaginal Ring Alters Vaginal Microbial Communities in Women With HIV

    by Nicole H Tobin, Sarah L Brooker, Fan Li, Robert W Coombs, Susan E Cohn, Laura Moran, Mey Leon, Nuntisa Chotirosniramit, Emilia M Jalil, Unoda A Chakalisa, et al.

    HIV-1 antiretroviral therapy (ART) alters hormonal contraceptive levels delivered via intravaginal ring (IVR) in a regimen specific manner. We explored the role of the IVR on vaginal microbial communities, vaginal short chain fatty acids (SCFAs), vaginal HIV shedding, and the effect of vaginal microbes on hormone concentrations in cisgender women with HIV (WWH). Vaginal microbes were assessed by 16S RNA sequencing of weekly vaginal swabs, vaginal SCFA by mass spectrometry, HIV-1 shedding by nucleic acid amplification on vaginal aspirates, and bacterial vaginosis by Nugent scoring from 74 participants receiving an etonorgestrel/ethinyl estradiol (ENG/EE) intravaginal ring while on no ART (N=25), efavirenz-based ART (N=25), or atazanavir-based ART (N=24). At baseline, microbial communities of the 64 substudy eligible participants robustly classified as Lactobacillus crispatus­-dominant (n=8), L. gasseri-dominant (n=2), L. iners-dominant (n=17), or mixed anaerobic communities (n=37). During IVR therapy, there was an increased probability of Lactobacillus-dominant community state types (CSTs) (odds-ratio=1.61, p=0.04). Vaginal CSTs were associated with Nugent scores. Bacterial vaginosis-associated bacteria were associated with significantly higher and L. iners with lower Nugent Scores (all p adj Lactobacillus species (r2=0.574; pL. crispatus-dominant microbiomes (p=0.04). Mixed anaerobic vaginal communities modulated EE concentrations in a regimen-specific manner. Combined ENG/EE IVR therapy was associated with an increase in Lactobacillus-dominant vaginal microbial communities in WWH and may benefit those with bacterial vaginosis. EE levels were altered by the vaginal microbiota.


  • Open Access

    NK Cell–Monocyte Cross-talk Underlies NK Cell Activation in Severe COVID-19

    by Madeline J. Lee, Izumi de Los Rios Kobara, Trisha R. Barnard, Xariana Vales Torres, Nicole H. Tobin, Kathie G. Ferbas, Anne W. Rimoin, Otto O Yang, Grace M. Aldrovandi, Aaron J. Wilk, et al.

    NK cells in the peripheral blood of severe COVID-19 patients exhibit a unique profile characterized by activation and dysfunction. Previous studies have identified soluble factors, including type I IFN and TGF-β, that underlie this dysregulation. However, the role of cell–cell interactions in modulating NK cell function during COVID-19 remains unclear. To address this question, we combined cell–cell communication analysis on existing single-cell RNA sequencing data with in vitro primary cell coculture experiments to dissect the mechanisms underlying NK cell dysfunction in COVID-19. We found that NK cells are predicted to interact most strongly with monocytes and that this occurs via both soluble factors and direct interactions. To validate these findings, we performed in vitro cocultures in which NK cells from healthy human donors were incubated with monocytes from COVID-19+ or healthy donors. Coculture of healthy NK cells with monocytes from COVID-19 patients recapitulated aspects of the NK cell phenotype observed in severe COVID-19, including decreased expression of NKG2D, increased expression of activation markers, and increased proliferation. When these experiments were performed in a Transwell setting, we found that only CD56bright CD16− NK cells were activated in the presence of severe COVID-19 patient monocytes. O-link analysis of supernatants from Transwell cocultures revealed that cultures containing severe COVID-19 patient monocytes had significantly elevated levels of proinflammatory cytokines and chemokines, as well as TGF-β. Collectively, these results demonstrate that interactions between NK cells and monocytes in the peripheral blood of COVID-19 patients contribute to NK cell activation and dysfunction in severe COVID-19.


  • Open Access

    Gut dysbiosis and inflammatory blood markers precede HIV with limited changes after early seroconversion

    by Jennifer A. Fulcher, Fan Li, Nicole H. Tobin, Sara Zabih, Julie Elliott, Jesse L. Clark, Richard D'AQuila, Brian Mustanski, Michele D. Kipke, Steven Shoptaw, et al.


  • Open Access

    Coronavirus Disease 2019 Vaccine Dosage in Children, Adolescents, and Young Adults: Is Less More?

    by Nicole H Tobin, Otto O Yang

    The lower efficacy of the COVID-19 mRNA vaccines in 5-11 year old children was unexpected. Neutralizing antibody titers elicited by the vaccines in children, adolescents, and young adults suggest that the lower efficacy is not due to the lower dosage. Confirming the efficacy of these vaccines in children, determining if mRNA vaccination strategies are less effective in younger children, as well as optimizing the dosage, dosing intervals, and number of doses needed in children, adolescents, and young adults are critical to improve vaccination strategies for these populations going forward.

  • Open Access

    Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection

    by Ashley N. Gray, Rachel Martin-Blais, Nicole H. Tobin, Yan Wang, Sarah L. Brooker, Fan Li, Adva Gadoth, Julie Elliott, Emmanuelle Faure-Kumar, Megan Halbrook, et al.

    Two mRNA vaccines (BNT162b2 and mRNA-1273) against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) are globally authorized as a two-dose regimen. Understanding the magnitude and duration of protective immune responses is vital to curbing the pandemic. We enrolled 461 high-risk health services workers at the University of California, Los Angeles (UCLA) and first responders in the Los Angeles County Fire Department (LACoFD) to assess the humoral responses in previously infected (PI) and infection naïve (NPI) individuals to mRNA-based vaccines (BNT162b2/Pfizer- BioNTech or mRNA-1273/Moderna). A chemiluminescent microparticle immunoassay was used to detect antibodies against SARS-CoV-2 Spike in vaccinees prior to (n = 21) and following each vaccine dose (n = 246 following dose 1 and n = 315 following dose 2), and at days 31–60 (n = 110) and 61–90 (n = 190) following completion of the 2-dose series. Both vaccines induced robust antibody responses in all immunocompetent individuals. Previously infected individuals achieved higher median peak titers (p = 0.002) and had a slower rate of decay (p = 0.047) than infection-naïve individuals. mRNA-1273 vaccinated infection-naïve individuals demonstrated modestly higher titers following each dose (p = 0.005 and p = 0.029, respectively) and slower rates of antibody decay (p = 0.003) than those who received BNT162b2. A subset of previously infected individuals (25%) required both doses in order to reach peak antibody titers. The biologic significance of the differences between previously infected individuals and between the mRNA-1273 and BNT162b2 vaccines remains uncertain, but may have important implications for booster strategies.


  • Open Access

    The systemic inflammatory landscape of COVID-19 in pregnancy: Extensive serum proteomic profiling of mother-infant dyads with in utero SARS-CoV-2

    by Suan-Sin Foo, Mary Catherine Cambou, Thalia Mok, Viviana M. Fajardo, Kyle L. Jung, Trevon Fuller, Weiqiang Chen, Tara Kerin, Jenny Mei, Debika Bhattacharya, et al.


  • Top Cited Papers
    Open Access

    Cross-sectional Assessment of COVID-19 Vaccine Acceptance Among Health Care Workers in Los Angeles

    by Adva Gadoth, Megan Halbrook, Rachel Martin-Blais, Ashley Gray, Nicole H. Tobin, Kathie G. Ferbas, Grace M. Aldrovandi, Anne W. Rimoin